Genprex (GNPX) Common Equity (2016 - 2026)
Genprex (GNPX) posted quarterly Common Equity of $16.9 million for Q1 2026, up 337.72% year-over-year from $3.9 million in Q1 2025, and up 112.64% quarter-over-quarter from $8.0 million in Q4 2025.
Genprex (GNPX) Common Equity (2016 - 2026) Analysis & Trends
Genprex's Common Equity history runs 11 years deep, the most recent figure standing at $16.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 337.72% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 337.72% YoY), while the FY2025 annual figure was $8.0 million, up 391.43% from the prior year.
- Common Equity for Q1 2026 stood at $16.9 million, up from $8.0 million in the prior quarter.
- The five-year high for Common Equity was $37.0 million in Q1 2022, with the low at $767807.0 in Q3 2025.
- The 5-year median for Common Equity is $8.8 million (2024), against an average of $12.8 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 86.47% in 2024, then soared 391.43% in 2025.
- Genprex's Common Equity stood at $22.3 million in 2022, then plunged by 66.7% to $7.4 million in 2023, then sank by 78.15% to $1.6 million in 2024, then soared by 391.43% to $8.0 million in 2025, then surged by 112.64% to $16.9 million in 2026.
- Business Quant data shows GNPX's Common Equity at $16.9 million in Q1 2026, $8.0 million in Q4 2025, and $767807.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Genprex | 1.91 Mn | -13.25 Mn | - | 14.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.93 Mn |
| Dec 31, 2025 | 7.96 Mn |
| Sep 30, 2025 | 767,807.00 |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 3.87 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 4.35 Mn |
| Mar 31, 2024 | 8.76 Mn |
| Dec 31, 2023 | 7.42 Mn |
| Sep 30, 2023 | 12.31 Mn |
| Jun 30, 2023 | 12.05 Mn |
| Mar 31, 2023 | 18.48 Mn |
| Dec 31, 2022 | 22.27 Mn |
| Sep 30, 2022 | 27.49 Mn |
| Jun 30, 2022 | 32.41 Mn |
| Mar 31, 2022 | 37.02 Mn |
| Dec 31, 2021 | 41.28 Mn |
| Sep 30, 2021 | 45.17 Mn |
| Jun 30, 2021 | 47.68 Mn |